Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK Rises
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday.
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was contaminated with a suspected carcinogen.
GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain
GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain.
7h
GSK plc (NYSE:GSK) Shares Purchased by SG Americas Securities LLC
SG Americas Securities LLC increased its position in GSK plc (NYSE:GSK – Free Report) by 167.3% in the third quarter, ...
STAT
3d
The company also agreed to pay $70 million to settle a whistleblower lawsuit
GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...
1d
GlaxoSmithKline (GSK) Gets a Hold from Kepler Capital
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
FiercePharma
3d
GSK will pony up $2.2B to resolve 80K Zantac cases
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
3d
GSK’s problem is it has more than one source of pain
Zantac settlement should ease investors’ nervousness but long-standing concerns about drugmaker’s pipeline remain ...
3d
GSK: The Worst Is Finally Over (Rating Upgrade)
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
2d
on MSN
GSK Bought More Shares of Biotech Wave Life Sciences
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
Buy
5d
GSK trial proves RSV vaccine efficacy after three full seasons
Finance News; GSK trial proves RSV vaccine efficacy after three full seasons; GSK trial proves RSV vaccine efficacy after three full seasons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback